Literature DB >> 10226073

Acidic fibroblast growth factor induces an antifibrogenic phenotype in human lung fibroblasts.

C Becerril1, A Pardo, M Montaño, C Ramos, R Ramírez, M Selman.   

Abstract

Acidic fibroblast growth factor (FGF-1), a prototype member of the heparin-binding growth factor family, influences proliferation, differentiation, and protein synthesis in different cell types. However, its possible role on lung extracellular matrix (ECM) metabolism has not been evaluated. In this study we examined the effects of FGF-1 and FGF-1 plus heparin on type I collagen, collagen-binding stress protein HSP47, interstitial collagenase (matrix metalloproteinase [MMP]-1), gelatinase A, and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 expression by normal human lung fibroblasts. Heparin was used because it enhances the biologic activities of FGF-1. Fibroblasts were exposed either to 20 ng/ml FGF-1 plus 100 micrograms/ml heparin for 48 h or to FGF-1 or heparin alone. Messenger RNA (mRNA) expression was analyzed by Northern blot. Collagen synthesis was evaluated by digestion of [3H]collagen with bacterial collagenase, MMP-1 by Western blot, and gelatinolytic activities by zymography. Our results show that FGF-1 induced collagenase mRNA expression, which was strongly enhanced when FGF-1 was used with heparin. Likewise, both FGF-1 and FGF-1 plus heparin reduced by 70 to 80% the expression of type I collagen transcript, in part through effect on pro-alpha1(I) collagen mRNA stability. A downregulation of HSP47 gene expression was also observed. Synthesis of collagen and collagenase proteins paralleled gene expression results. FGF-1 activities were abolished with genistein, a tyrosine kinase inhibitor. Neither FGF-1 nor FGF-1 plus heparin affected the expression of TIMP-1, TIMP-2, and gelatinase A. These findings demonstrate that FGF-1, mostly in the presence of heparin, upregulates collagenase and downregulates type I collagen expression that might have a protective role in avoiding collagen accumulation during lung ECM remodeling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226073     DOI: 10.1165/ajrcmb.20.5.3288

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  16 in total

1.  Synthesis of multilayered alginate microcapsules for the sustained release of fibroblast growth factor-1.

Authors:  Omaditya Khanna; Monica L Moya; Emmanuel C Opara; Eric M Brey
Journal:  J Biomed Mater Res A       Date:  2010-11       Impact factor: 4.396

2.  Expression of basic fibroblast growth factor in rat liver fibrosis and hepatic stellate cells.

Authors:  Xiaodong Peng; Bo Wang; Tancai Wang; Qiu Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

4.  Activation of heat shock response augments fibroblast growth factor-1 expression in wounded lung epithelium.

Authors:  Rachel G Scheraga; Christopher Thompson; Mohan E Tulapurkar; Ashish C Nagarsekar; Mark Cowan; Ratnakar Potla; Junfeng Sun; Rongman Cai; Carolea Logun; James Shelhamer; Nevins W Todd; Ishwar S Singh; Irina G Luzina; Sergei P Atamas; Jeffrey D Hasday
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-16       Impact factor: 5.464

Review 5.  Fine-tuning vascular fate during endothelial-mesenchymal transition.

Authors:  Lin Xiao; Andrew C Dudley
Journal:  J Pathol       Date:  2016-11-10       Impact factor: 7.996

Review 6.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Authors:  Vanessa J Craig; Li Zhang; James S Hagood; Caroline A Owen
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

Review 7.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-06       Impact factor: 84.694

8.  Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.

Authors:  BreAnne MacKenzie; Martina Korfei; Ingrid Henneke; Zaneta Sibinska; Xia Tian; Stefanie Hezel; Salma Dilai; Roxana Wasnick; Beate Schneider; Jochen Wilhelm; Elie El Agha; Walter Klepetko; Werner Seeger; Ralph Schermuly; Andreas Günther; Saverio Bellusci
Journal:  Respir Res       Date:  2015-07-03

9.  C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice.

Authors:  Toru Kimura; Takashi Nojiri; Jun Hino; Hiroshi Hosoda; Koichi Miura; Yasushi Shintani; Masayoshi Inoue; Masahiro Zenitani; Hiroyuki Takabatake; Mikiya Miyazato; Meinoshin Okumura; Kenji Kangawa
Journal:  Respir Res       Date:  2016-02-19

Review 10.  Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Authors:  Minoru Inomata; Yasuhiko Nishioka; Arata Azuma
Journal:  Core Evid       Date:  2015-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.